Alvos Moleculares dos Fármacos no Tratamento da COVID-19

Autores

  • Irineu Ferreira da Silva Neto Faculdade de Medicina Estácio de Juazeiro do Norte
  • Isadora Ellen Feitoza Ricardino Faculdade de Medicina Estácio de Juazeiro do Norte
  • Maria Nathalya Costa Souza Faculdade de Medicina Estácio de Juazeiro do Norte
  • Rafael de Carvalho Mendes Faculdade de Medicina Estácio de Juazeiro do Norte

DOI:

https://doi.org/10.9771/cp.v13i5.38061

Palavras-chave:

COVID-19, Mecanismo de ação, Tratamento.

Resumo

Devido à pandemia da COVID-19, vários pesquisadores estão buscando estratégias farmacológicas para o tratamento dessa enfermidade. Neste artigo pretende-se expor os alvos farmacológicos mais relevantes encontrados na literatura e que estão frequentemente sendo utilizados no tratamento da COVID-19. Foi realizada uma revisão de literatura por meio de busca nas bases de dados eletrônicas: SciELO e PubMed, para tanto, utilizou-se os seguintes descritores: Fármacos “Drugs”, Tratamento “Treatment” e COVID-19. Selecionou-se publicações entre dezembro de 2019 a junho de 2020. Entre os fármacos mais utilizados no tratamento da COVID-19, estão: Redemsivir, Favipiravir, Ribavirina, Arbidol, Hidroxicloroquina, Azitromicina, Interferon, combinado com beta-1b, e associação entre Lopinavir/Ritonavir. Os alvos dessas drogas incluem a inibição da RNA polimerase dependente, a fusão do vírus com a membrana da célula alvo, a acidificação endossômica e a exocitose viral e da protease do tipo papaína e 3C. Ressalta-se a importância de estudos controlados e específicos de acordo com cada país, visto que o perfil fisiológico da população se mostra diferente para cada uma.

Downloads

Não há dados estatísticos.

Biografia do Autor

Irineu Ferreira da Silva Neto, Faculdade de Medicina Estácio de Juazeiro do Norte

Discente do curso de Fármacia na Faculdade de Medicina Estácio de Juazeiro do Norte

Isadora Ellen Feitoza Ricardino, Faculdade de Medicina Estácio de Juazeiro do Norte

Discente do curso de Fármacia na Faculdade de Medicina Estácio de Juazeiro do Norte

Maria Nathalya Costa Souza, Faculdade de Medicina Estácio de Juazeiro do Norte

Discente do curso de Fármacia na Faculdade de Medicina Estácio de Juazeiro do Norte

Rafael de Carvalho Mendes, Faculdade de Medicina Estácio de Juazeiro do Norte

Docente do curso de Fármacia na Faculdade de Medicina Estácio de Juazeiro do Norte

Referências

ALI, I.; ALHARBI, O.M.L. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ, [S.l.], v. 728, p. 138861, 2020. DOI:10.1016/j.scitotenv.2020.138861.

ANTINORI, S. et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res., [S.l.], v. 158, p. 104899, 2020. DOI:10.1016/j.phrs.2020.104899.

ARSHAD, S. et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis., [S.l.], v. 97, p. 396-403, 2020. DOI:10.1016/j.ijid.2020.06.099.

BALACHANDAR, Vellingiri et al. Follow-up studies in COVID-19 recovered patients-is it mandatory? Science of The Total Environment, [S.l.], p. 139021, 2020. DOI: 10.1016/j.scitotenv.2020.139021.

BRASIL. Painel de casos de doença pelo coronavírus 19 (COVID-19) no Brasil pelo Ministério da Saúde. Brasília (DF): Ministério da Saúde, 2020a. Disponível em: https://covid.saude.gov.br/. Acesso em: 24 jul. 2020.

BRASIL. Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes diagnosticados da COVID-19. Brasília (DF): Ministério da Saúde, 2020b. Disponível em: https://saude.gov.br/images/pdf/2020/June/18/COVID-FINAL-16JUNHO-LIvreto-1-V3.pdf. Acesso em: 24 jul. 2020.

CAI, Qingxian et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering, [S.l.], v. 10, p. 1016, 2020. DOI: 10.1016/j.eng.2020.03.007.

CAO, Bin et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, [S.l.], v. 382, n. 19, p. 1.787-1.799, 2020. DOI: 10.1056/NEJMoa2001282.

CFF – CONSELHO FEDERAL DE FARMÁCIA. Levantamento mostra como o medo da Covid-19 impactou venda de medicamentos. 2020. Disponível em: https://www.cff.org.br/noticia.php?id=5747. Acesso em: 24 ago. 2020.

COOMES, E. A.; HAGHBAYAN, H. Favipiravir, an antiviral for COVID-19? The Journal of Antimicrobial Chemotherapy, [S.l.], v. 75, n. 7, p. 2.013-2.014, 2020. DOI: 10.1093/jac/dkaa171.

COENEN, Samuel et al. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018. British Journal of General Practice, [S.l.], v. 70, n. 696, p. e444-e449, 2020. DOI:10.3399/bjgp20X711941.

CRODA, Julio et al. COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases. Rev. Soc. Bras. Med. Trop., Uberaba, v. 53, e. 20200167, 2020. DOI: 10.1590/0037-8682-0167-2020.

DALAMAGA, M.; KARAMPELA, I.; MANTZOROS, C. S. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens? Metabolism: Clinical and Experimental. [S.l.], v. 108, p. 154-260, 2020. DOI: 10.1016/j.metabol.2020.154260.

DE SOUZA MORAIS, Williams Raphael et al. Investigação Prospectiva do Novo Coronavírus e de Fármacos Antivirais com Potencial Atividade Terapêutica para o Tratamento de Pacientes Infectados pela COVID-19. Cadernos de Prospecção, Salvador, v. 13, n. 3, p. 619, 2020. DOI: 10.9771/cp.v13i3.36384.

DENG, L. et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect., [S.l.], v. 81, n. 1, p. e1-e5, 2020. DOI: 10.1016/j.jinf.2020.03.002.

DU, Y. X.; CHEN, X. P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clinical pharmacology and therapeutics, [S.l.], v. 108, n. 2, p. 242-247, 2020. DOI: 10.1002/cpt.1844.

EASTMAN, R. T. et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS central Science, [S.l.], v. 6, n.5, p. 672-683, 2020. DOI: 10.1021/acscentsci.0c00489.

ESPOSITO, S.; NOVIELLO, S.; PAGLIANO, P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni Med, [S.l.], v. 2, p. 198-211, 2020.

GAUTRET, Philippe et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Medicine and Infectious Disease, [S.l.], n. 34, p. 101-663, 2020. DOI: 10.1016/j.tmaid.2020.101663.

GRANT, William B. et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients, [S.l.], v. 12, n. 4, p. 988, 2020. DOI: 10.3390/nu12040988.

GREIN, Jonathan et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England Journal of Medicine, [S.l.], v. 382, n. 24, p. 2.327-2.336, 2020. DOI: 10.1056/NEJMoa2007016.

GUL, M. H. et al. Potential specific therapies in COVID-19. Therapeutic Advances in Respiratory Disease, [S.l.], v. 14, 2020. DOI: 10.1177/1753466620926853.

HUNG, Ivan Fan-Ngai et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, [S.l.], v. 395, n. 10238, p. 1.695-1.704, 2020. DOI: 10.1016/S0140-6736(20)31042-4.

JEAN, S. S.; LEE, P. I.; HSUEH, P. R. Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology, and Infection = Wei mian yu gan ran za zhi, [S.l.], v. 53, n. 3, p. 436-443, 2020. DOI: 10.1016/j.jmii.2020.03.034.

KHALILI, J. S. et al. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol., [S.l.], v. 92, n. 7, p. 740-746, 2020. DOI: 10.1002/jmv.25798.

LI, Heng et al. Coronavirus disease 2019 (COVID-19): current status and future perspective. International Journal of Antimicrobial Agents, [S.l.], v. 55, n. 5, p. 105951, 2020. DOI: 10.1016/j.ijantimicag.2020.105951.

LIPWORTH, B.; KUO, C. R.; CHAN, R. Emerging pharmacotherapy for COVID-19. The journal of the Royal College of Physicians of Edinburgh, [S.l.], v. 50, n. 2, p. 133-137, 2020. DOI:10.4997/JRCPE.2020.210.

LIU, Fang et al. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open, [S.l.], v. 10, n. 7, p. e039519, 2020. DOI: 10.1136/bmjopen-2020-039519.

LU, C. C. et al. Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association: JCMA, [S.l.], v. 83, n. 6, p. 534-536, 2020. DOI: 10.1097/JCMA.0000000000000318.

LU, I. N. et al. MuLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials, [S.l.], v. 21, n. 1, p. 690, 2020. DOI: 10.1186/s13063-020-04618-2.

ORLEANS, L. A.; IS VICE, H.; MANCHIKANTI, L. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician, [S.l.], v. 23, p. E71-E83, 2020.

PANTOS, Constantinos et al. Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Trials, [S.l.], v. 21, n. 1, p. 1-3, 2020. DOI:10.1186/s13063-020-04474-0.

PILKINGTON, Victoria; PEPPERRELL, Toby; HILL, Andrew. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic? Journal of Virus Eradication, [S.l.], v. 6, n. 2, p. 45, 2020. DOI: 10.1016/S2055-6640(20)30016-9.

PLAZE, M. et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale, [S.l.], v. 46, n. 3, p.169-172, 2020. DOI:10.1016/j.encep.2020.05.006.

QUINTELLA, Cristina M. et al. Fármacos para COVID-19: muito além da cloroquina (testes clínicos para o coronavírus SARS-CoV-2). Cadernos de Prospecção, Salvador, v. 13, n. 3, p. 599, 2020. DOI: 10.9771/cp.v13i3.36815.

ROSA, S. G. V.; SANTOS, W. C. Ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19. Revista Panamericana de Salud Pública, [S.l.], v. 44, n.40, p. 1-7, 2020. DOI: 10.26633/RPSP.2020.40.

SAHA, A. et al. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. Archives of Medical Research, [S.l.], S0188-4409 n. 20, p. 30699-8, 2020. Advance online publication. DOI: 10.1016/j.arcmed.2020.05.001.

SANDERS, J. M. et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama, [S.l.], v. 323, n. 18, p. 1.824-1.836, 2020. DOI: 10.1001/jama.2020.6019.

SEVILLA-SÁNCHEZ, D.; TUSET-CREUS, M. La atención farmacéutica en pacientes ingresados. Revista Farmacia Hospitalaria, [S.l.], v. 44, n. 1, p. 28-31, 2020. DOI: https://doi:10.7399/fh.11513.

SILVA, Francielle Santos da et al. Evaluation of recombinant human interferon beta 1b by liquid chromatography methods and bioassay. Braz. J. Pharm. Sci., São Paulo, v. 55, p. 18328, 2019. DOI: 10.1590/s2175-97902019000218328.

ŞIMŞEK YAVUZ, S.; ÜNAL, S. Tratamento antiviral de COVID-19. Turk J Med. Sci., [S.l.], v. 50 n. 1, p. 611‐619, 2020. Published 2020 Apr 21. DOI: 10.3906 / sag-2004-145.

SIRBU, Carmen Adella et al. Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review. Medicina, [S.l.], v. 56, n. 4, p. 202, 2020. DOI: 10.3390/medicina56040202.

TANG, Wei et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ (Clinical Research ed.), [S.l.], n. 369, p.1849, 2020. DOI: 10.1136/bmj.m1849.

TRIGGLE, Chris R. et al. COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. Msphere, [S.l.], v. 5, n. 3, 2020. DOI:10.1128/mSphere.00317-20.

VANKADARI, Naveen. Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein?. International Journal of Antimicrobial Agents, [S.l.], v. 56, n. 2, p. 105998, 2020. DOI:10.1016/j.ijantimicag.2020.105998.

WANG, Huihui et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, [S.l.], v. 39, n. 9, 1629-1635, 2020. DOI:10.1007/s10096-020-03899-4.

WANG, Yeming et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England), [S.l.], v. 395 n. 10236, 1569–1578, 2020. DOI: 10.1016/S0140-6736(20)31022-9.

WILKINSON, Tom et al. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, [S.l.], v. 21, n. 1, p. 1-3, 2020. DOI:10.1186/s13063-020-04584-9.

WONG, Anselm. COVID-19 e toxicidade de tratamentos potenciais: Panaceia ou veneno. Medicina de emergência Australasia: EMA, [S.l.], v. 32, n. 4, 697-699, 2020. DOI:10.1111/1742-6723.13537

YE, Qingsong et al. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I/II). Trials, [S.l.], v. 21, n. 1, p. 1-4, 2020. DOI:10.1186/s13063-020-04380-5.

YE, X. T. et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci, [S.l.], v. 24, n. 6, p. 3390-3396, 2020. DOI:10.26355/eurrev_202003_20706.

YU, S.; WANG, J.; SHEN, H. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19. Annals of Palliative Medicine, [S.l.], v. 9, n. 2, p. 437-446, 2020. DOI: 10.21037/apm.2020.03.27.

ZHAI, Pan et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents, [S.l.], v. 55, n. 5, p. 105-955, 2020. DOI: 10.1016/j.ijantimicag.2020.105955.

ZHENG, J. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. International Journal of Biological Sciences, [S.l.], v. 16, n. 10, p. 1.678-1.685, 2020. DOI: 10.7150/ijbs.45053.

ZHU, Z. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. The Journal of Infection, [S.l.], v. 81, n.1, p. e21-e23, 2020. DOI:10.1016/j.jinf.2020.03.060.

Downloads

Publicado

2020-10-01

Como Citar

Neto, I. F. da S., Ricardino, I. E. F., Souza, M. N. C., & Mendes, R. de C. (2020). Alvos Moleculares dos Fármacos no Tratamento da COVID-19. Cadernos De Prospecção, 13(5), 1251. https://doi.org/10.9771/cp.v13i5.38061

Edição

Seção

Coronavirus (SARS-COV-2) e COVID-19